# Efficacy and Safety of CUSA-081 in the Restoration of Central Venous Access Device (CVAD) Functionality

> **NCT03594175** · PHASE3 · TERMINATED · sponsor: **Chiesi Farmaceutici S.p.A.** · enrollment: 462 (actual)

## Conditions studied

- Catheter Occlusion
- Thrombosis

## Interventions

- **DRUG:** CUSA-081
- **DRUG:** Placebo
- **DRUG:** Alteplase

## Key facts

- **NCT ID:** NCT03594175
- **Lead sponsor:** Chiesi Farmaceutici S.p.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-02-12
- **Primary completion:** 2023-06-08
- **Final completion:** 2023-07-10
- **Target enrollment:** 462 (ACTUAL)
- **Why stopped:** Due to ongoing recruitment challenges globally, it is not possible to complete this study. The decision is not based on any reported changes in the safety profile or any concerns with the anticipated efficacy profile of the investigational product.
- **Last updated:** 2024-08-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03594175

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03594175, "Efficacy and Safety of CUSA-081 in the Restoration of Central Venous Access Device (CVAD) Functionality". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03594175. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*